Effect of Proprietary Chinese Medicine on Coronary Microvascular Dysfunction in Patients with Microvascular Angina: A Systematic Review and Meta-Analysis

Table 7

Subgroup analysis of NO based-on dosage form, drug, sample size, treatment duration, sex ratio, average age, location, and year.

Items	Subgroup	n	SMD (95% CI)	I ^2 (%)	z
Dosage form	Pill	3	1.11 (0.47, 1.76)	78.4	3.373	0.001
	Dropping pill	1	0.81 (0.42, 1.21)	—	4.017	<0.001
	Capsule	7	1.42 (0.95, 1.90)	82.9	5.900	<0.001
Drug	YXLC	3	1.03 (0.55, 1.51)	52.2	4.232	<0.001
	SBP	2	1.15 (0.05, 2.24)	89.2	2.052	0.040
	YXSC	2	1.18 (0.89, 1.46)	0.0	7.984	<0.001
Sample size	≥80	4	1.16 (0.87, 1.45)	45.4	7.872	<0.001
	<80	7	1.35 (0.78, 1.98)	86.4	4.611	<0.001
Treatment duration	≥6 months	3	1.05 (0.77, 1.33)	21.4	7.267	<0.001
	<6 months	8	1.39 (0.90, 1.87)	84.7	5.626	<0.001
Sex ratio	F/M ≥ 100%	9	1.37 (0.97, 1.76)	81.7	6.756	<0.001
	F/M < 100%	2	0.89 (0.32, 1.46)	64.7	3.068	0.002
Average age	>60	4	1.67 (0.87, 2.48)	91.3	4.062	<0.001
	<60	7	1.07 (0.79, 1.35)	49.5	7.510	<0.001
Location	North	7	1.39 (0.89, 1.89)	86.1	5.407	<0.001
	South	4	1.10 (0.73, 1.48)	51.2	5.819	<0.001
Year	2016	2	0.65 (0.30, 1.00)	0.0	3.655	<0.001
	2018	2	1.53 (1.16, 1.90)	0.0	8.042	<0.001
	2019	2	1.12 (0.77, 1.47)	0.0	6.295	<0.001